On November 22, 2024, Rachel Mcminn, the CEO of Neurogene Inc, acquired 47,500 shares of the company, as reported in a recent SEC Filing. Following this transaction, the insider now holds a total of 1,297,859 shares in the company.
Neurogene Inc (NGNE, Financial) is a biotechnology company focused on developing life-changing genetic medicines for patients and families affected by rare neurological diseases. The company's mission is to bring transformative therapies to those with limited or no treatment options.
The insider's recent purchase is part of a broader trend of insider buying at Neurogene Inc. Over the past year, there have been two insider buys and no insider sells, indicating a positive sentiment among the company's leadership.
On the day of the purchase, shares of Neurogene Inc were trading at $20.40 each, resulting in a market cap of $331.483 million for the company. This transaction reflects the insider's confidence in the company's future prospects and aligns with the overall insider buying trend observed over the past year.
For more information on the company's valuation metrics, such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors can explore further details on the company's financial performance and market position.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
